Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.30 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30010765 | 1.00 | TRPV4 (0.38) | TRPV4L3MBTL1SLC9A1SLC9A2ALDH1A1 | |
| Tetrazole SCHEMBL9634294 | 0.82 | — | — | |
| SCHEMBL971368 | 0.82 | L3MBTL1 (0.32) | L3MBTL1SLC9A1SLC9A2ALDH1A1HPGD | |
| SCHEMBL719443 | 0.80 | FABP3 (0.41) | L3MBTL1SLC9A1SLC9A2ALDH1A1HPGD | |
| SCHEMBL3925075 | 0.80 | CA1 (0.39) | L3MBTL1SLC9A1SLC9A2ALDH1A1 | |
| SCHEMBL10980384 | 0.80 | L3MBTL1 (0.32) | L3MBTL1SLC9A1SLC9A2ALDH1A1HPGD | |
| SCHEMBL10435622 | 0.78 | L3MBTL1 (0.31) | L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1005423 | 0.78 | FABP3 (0.40) | L3MBTL1SLC9A1SLC9A2HPGD | |
| Ammonia Solution, Strong SCHEMBL11578768 | 0.78 | FABP3 (0.40) | L3MBTL1SLC9A1SLC9A2HPGD | |
| SCHEMBL9164110 | 0.78 | SLC9A1 (0.33) | L3MBTL1SLC9A1SLC9A2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105910-B | Hydroxycarbamimidoyl phenylalanine derivative, pharmaceutical composition and application | 北京悦康科创医药科技股份有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-110590547-A | Method for synthesizing prostacyclin derivative | 开曼化学股份有限公司 | 2019-12-20 | — | — | CN | claimed |
| US-10155716-B2 | Amine salts of a prostacyclin analog | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2018-12-18 | — | — | US | claimed |
| US-20180141889-A1 | METHODS OF SYNTHESIZING A PROSTACYCLIN ANALOG | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2018-05-24 | — | — | US | claimed |
| US-20180118656-A1 | AMINE SALTS OF A PROSTACYCLIN ANALOG | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2018-05-03 | — | — | US | claimed |
| CN-107033601-A | A kind of cable for solar photovoltaic generation system | 安徽省无为县经纬电缆附件有限公司 | 2017-08-11 | — | — | CN | claimed |
| US-20160289158-A1 | Amine Salts of a Prostacyclin Analog | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2016-10-06 | — | — | US | claimed |
| EP-3068752-A1 | AMINE SALTS OF A PROSTACYCLIN ANALOG | Cayman Chemical Company Incorporated (US) | 2016-09-21 | — | — | EP | claimed |
| CN-105722812-A | Amine salts of prostacyclin analog | 开曼化学股份有限公司 | 2016-06-29 | — | — | CN | claimed |
| US-20150315114-A1 | Methods of Synthesizing a Prostacyclin Analog | CAYMAN CHEMICAL COMPANY INCORPORATED | 2015-11-05 | — | — | US | claimed |
| CN-1714094-A | Cardiolipin compositions their methods of preparation and use | NEOPHARM INC (US) | 2005-12-28 | — | — | CN | claimed |
| US-20050181037-A1 | Cardiolipin compositions their methods of preparation and use | NEOPHARM, INC. (US) | 2005-08-18 | — | — | US | claimed |
| EP-1513853-A2 | CARDIOLIPIN COMPOSITIONS, METHODS OF PREPARATION AND USE | Neopharm, Inc. (US) | 2005-03-16 | — | — | EP | claimed |
| WO-2004062569-A2 | CARDIOLIPIN COMPOSITIONS THEIR METHODS OF PREPARATION AND USE | NEOPHARM, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| WO-2003099830-A2 | CARDIOLIPIN COMPOSITIONS, METHODS OF PREPARATION AND USE | NEOPHARM, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| EP-1155027-B1 | SYNTHESIS OF LABELLED OLIGONUCLEOTIDES ON SOLID-SUPPORTS | APPLERA CORP (US) | 2003-10-01 | — | — | EP | claimed |
| US-6255476-B1 | REACTING A LABELLED SOLID SUPPORT OF GIVEN FORMULA TO REMOVE AN ACID CLEAVABLE PROTECTING GROUP, ADDING A 5'-PHOSPHORAMIDITE, 3'-PROTECTED NUCLEOSIDE AND AN ACTIVATOR TO FROM A BOND | PE CORPORATION (NY) | 2001-07-03 | — | — | US | claimed |
| US-6096916-A | Synthesis of D-3 phosphorylated phosphoinositides and analogues | NUTRIMED BIOTECH (US) | 2000-08-01 | — | — | US | claimed |
| US-5644048-A | Process for preparing phosphorothioate oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 1997-07-01 | — | — | US | claimed |
| WO-1994019363-A1 | PROCESS FOR PREPARING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1994-09-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289158-A1 | Amine Salts of a Prostacyclin Analog | PTGIS, PTGIR, PTGER1 | TRPV4 1019/4885L3MBTL1 4874/4885SLC9A1 474/4885 |
| US-20150315114-A1 | Methods of Synthesizing a Prostacyclin Analog | PTGIS, CYP11B2, CYP11B1 | TRPV4 1706/4885L3MBTL1 3600/4885SLC9A1 921/4885 |
| US-20180141889-A1 | METHODS OF SYNTHESIZING A PROSTACYCLIN ANALOG | PTGIS, CYP11B1, CYP11B2 | TRPV4 2000/4885L3MBTL1 3475/4885SLC9A1 979/4885 |
| US-20050181037-A1 | Cardiolipin compositions their methods of preparation and use | LIPA, LCLAT1, PHOSPHO1 | TRPV4 3420/4885L3MBTL1 2597/4885SLC9A1 1696/4885 |
| US-10155716-B2 | Amine salts of a prostacyclin analog | PTGIS, PTGIR, PTGER1 | TRPV4 1019/4885L3MBTL1 4874/4885SLC9A1 474/4885 |
| US-20180118656-A1 | AMINE SALTS OF A PROSTACYCLIN ANALOG | PTGIS, PTGIR, PTGER1 | TRPV4 1019/4885L3MBTL1 4874/4885SLC9A1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.